Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Carl Zeiss Meditec AG    AFX   DE0005313704

CARL ZEISS MEDITEC AG

(AFX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Carl Zeiss Meditec : Continued profitable growth for Carl Zeiss Meditec in the first three months of 2018/19

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 01:05am EDT

DGAP-News: Carl Zeiss Meditec AG / Key word(s): Quarterly / Interim Statement/Quarter Results
Continued profitable growth for Carl Zeiss Meditec in the first three months of 2018/19

11.02.2019 / 07:00
The issuer is solely responsible for the content of this announcement.


Continued profitable growth for Carl Zeiss Meditec in the first three months of 2018/19
 
Successful start to new fiscal year, with both strategic business units contributing
 

JENA, February 11, 2019

In the first three months of fiscal year 2018/19 Carl Zeiss Meditec generated revenue of EUR323.6m, representing an increase of 9.8% (adjusted for currency effects: +9.0%) compared with the same period of the previous year (prior year: EUR294.7m). Significant growth was posted in the EMEA[1] region, particularly in its core markets Germany, France and Southern Europe. Earnings before interest and taxes (EBIT) increased significantly to EUR48.1m (prior year: EUR38.9m). The EBIT margin also increased, to 14.9% (prior year: 13.2%).

"We have made a successful start to the new financial year and were able to further expand our market share in both strategic business units," explains Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.

Solid growth in both strategic business units

The Ophthalmic Devices strategic business unit (SBU) increased its revenue by 10.7 percent in the first three months of fiscal year 2018/19 (adjusted for currency effects: +9.8 percent), to EUR239.5m, compared with EUR216.3m in the same period of the prior year. This revenue increase was mainly attributable to laser vision correction systems as well as devices and consumables in cataract surgery.

Revenue in the Microsurgery SBU grew by 7.4 percent (adjusted for currency effects: +6.7 percent), to EUR84.2m, compared with EUR78.4m in the same period of the prior year. Sales of neurosurgical visualization systems for the treatment of tumors and vascular disease also remained buoyant.

Significant growth, particularly in the EMEA region

Revenue in the EMEA region increased by 13.5 percent (adjusted for currency effects: +15.1 percent), to EUR103.5m (prior year: EUR91.2m). Germany, France and Southern Europe posted strong revenue growth.

At EUR91.9m (prior year: EUR94.1; -2.3%, adjusted for currency effects: -4.9%), revenue in the first three months of the current fiscal year in the Americas region was slightly below the prior year's figure. This development is primarily attributable to new product launches at the beginning of the 2017/18 fiscal year, which had provided a strong boost to revenue in the same period of the prior year.

The APAC[2] region also posted a further increase in its revenue, of 17.1% (adjusted for currency effects: +16.2%) to EUR128.2m (prior year: EUR109.5m).

The operating result (earnings before interest and taxes: EBIT) increased significantly and reached EUR48.1m in the first three months of the current fiscal year (prior year: EUR38.9m). The EBIT margin increased from 13.2 percent to 14.9 percent. Adjusted for special effects, this represented an increase of 15.1% (prior year: 13.5 percent). Earnings of EUR0.32 per share remained at the same level as the previous year.

For fiscal 2018/19, we are expecting to grow at least as fast as our markets, which is confirmed by our business performance in the last three months. We are also holding to our margin target. We are expecting an EBIT margin in the range of 14 to 16 percent in the current fiscal year and in the medium term," said Dr. Monz, confirming the forecast published in December 2018.
 

Revenue by strategic business unit

All figures in EURm 3 months 2018/19 3 months 2017/18 Change from prior year Change from prior year (adjusted for currency effects)
Ophthalmic Devices 239.5 216.3 +10.7% +9.8%
Microsurgery 84.2 78.4 +7.4% +6.7%
Overall group 323.6 294.7 +9.8% +9.0%
 

 

Revenue by region

All figures in EURm 3 months 2018/19 3 months 2017/18 Change from prior year Change from prior year (adjusted for currency effects)
EMEA 103.5 91.2 +13.5% +15.1%
Americas 91.9 94.1 -2.3% -4.9%
APAC 128.2 109.5 +17.1% +16.2%
Overall group 323.6 294.7 +9.8% +9.0%
 

 

Contact for investors and press
Sebastian Frericks
Director Investor Relations, Carl Zeiss Meditec AG
Phone: +49 (0)3641 220-116
Email: investors.meditec@zeiss.com

www.zeiss.de/presse

[1] Europe, Middle East, Africa
[2] Asia/Pacific



11.02.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.meditec@zeiss.com
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

774205  11.02.2019 

fncls.ssp?fn=show_t_gif&application_id=774205&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARL ZEISS MEDITEC AG
05/06GLOBAL MARKETS LIVE : Boeing, Berkshire Hathaway, Airbus, Occidental Petroleum…
05/06CARL ZEISS MEDITEC : First half year 2018/2019: Continued profitable growth for ..
PU
05/06CARL ZEISS MEDITEC : Continued profitable growth for Carl Zeiss Meditec
EQ
04/29CARL ZEISS MEDITEC : ZEISS PLEX Elite 2.0 at ARVO
AQ
04/29CARL ZEISS MEDITEC AG : Preliminary announcement of the publication of financial..
EQ
04/12European shares end higher boosted by banks and auto stocks
RE
04/12CARL ZEISS MEDITEC : reports further growth and defines expectations for fiscal ..
EQ
04/04Medical Imaging Workstations Market 2026 Trends, Top Companies - Ampronix, Ca..
AQ
03/20CARL ZEISS MEDITEC : Ex-dividend day for final dividend
FA
03/11CARL ZEISS MEDITEC : FDA Clearance for Epithelial Thickness Mapping
AQ
More news
Financials (€)
Sales 2019 1 410 M
EBIT 2019 235 M
Net income 2019 162 M
Finance 2019 658 M
Yield 2019 0,70%
P/E ratio 2019 49,60
P/E ratio 2020 41,80
EV / Sales 2019 5,12x
EV / Sales 2020 4,64x
Capitalization 7 880 M
Chart CARL ZEISS MEDITEC AG
Duration : Period :
Carl Zeiss Meditec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARL ZEISS MEDITEC AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 80,6 €
Spread / Average Target -8,5%
EPS Revisions
Managers
NameTitle
Ludwin Monz President & Chief Executive Officer
Michael Kaschke Chairman-Supervisory Board
Justus Felix Wehmer Chief Financial Officer
Markus Guthoff Member-Supervisory Board
Cornelia Grandy Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
CARL ZEISS MEDITEC AG28.99%8 827
THERMO FISHER SCIENTIFIC21.10%108 715
DANAHER CORPORATION27.65%94 532
INTUITIVE SURGICAL-0.50%55 015
BOSTON SCIENTIFIC CORPORATION6.93%53 498
ILLUMINA3.01%45 930